Literature DB >> 1352078

Arguments against the prostatic origin of the R-3327 Dunning H tumor.

H W Goebel1, U Rausch, M Steinhoff, J Seitz, M Bacher, M Papotti, G Bussolati, P Tuohimaa, G Aumüller.   

Abstract

The Dunning tumor, originally described as a carcinoma of the rat dorsal prostate, has for long been used as an experimental model of prostatic cancer. We have recently presented a number of morphological findings that are incompatible with the prostatic origin of the H-subline of the Dunning tumor. In this paper, biochemical and immunohistochemical markers of rat prostate and mammary gland are studied in the R-3327 Dunning H tumor. Pieces of the H tumor were inoculated in male or lactating female rats. The electrophoretic protein pattern of Dunning tumor extracts was more similar to that of the mammary gland than the dorsolateral prostate. Proteins selectively appearing after metabolic labeling in Dunning tumors grown in lactating rats corresponded to labeled proteins in mammary glands from the same animals. Secretory proteins typical of the lateral prostate (SVS II) and dorsal prostate (transglutaminase) could not be detected immunohistochemically in the Dunning tumor. Western blot studies of tumor extracts and slot blot analysis of RNA preparations from the tumor confirmed the absence of SVS II and prostate specific transglutaminase from the Dunning tumor. On the other hand, the presence of mammary gland proteins such as milk fat globule membrane proteins, lactoperoxidase and lactalbumin were detected in the Dunning tumor by immunohistochemistry and Western blotting, but were absent from the dorsolateral prostate. Transferrin-mRNA, expressed in the male urogenital tract and also in the liver and other tissues, was detected in the mammary gland and Dunning tumor, but not in the dorsolateral prostate. The absence of mammary gland secretory beta-casein in the Dunning tumor was related to the elevated Ha-ras oncogene expression in the tumor, previously reported to suppress casein expression. The findings clearly demonstrate that the prostate cannot be the origin of the Dunning tumor, presently being used in prostatic cancer research. The designation prostatic adenocarcinoma for this tumor is therefore invalid. Furthermore, the data support our view that mammary gland might be the origin of the Dunning tumor, although the derivation from the bulbourethral or the parotid glands cannot strictly be excluded.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1352078     DOI: 10.1007/bf02899660

Source DB:  PubMed          Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol        ISSN: 0340-6075


  2 in total

1.  Tissue-type transglutaminase expression in the Dunning tumor.

Authors:  A Wunsch; U Rausch; J Seitz; H W Goebel; B Friedrichs; G Aumüller
Journal:  Urol Res       Date:  1993-01

2.  PTEN knockout prostate cancer as a model for experimental immunotherapy.

Authors:  Kazunori Haga; Atsushi Tomioka; Chun-Peng Liao; Takahiro Kimura; Hiroshi Matsumoto; Izumi Ohno; Kip Hermann; Christopher R Logg; Jing Jiao; Motoyoshi Tanaka; Yoshihiko Hirao; Hong Wu; Carol A Kruse; Pradip Roy-Burman; Noriyuki Kasahara
Journal:  J Urol       Date:  2008-11-17       Impact factor: 7.450

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.